CYNTHIA S. SCHWALM

Corporate Board Profile

Tech Score: 0/100

LISATA THERAPEUTICS, INC.

Filing Date	Source Excerpt
2020-04-29	Ms. Schwalm currently serves on the board of Kadmon Group, Inc., a clinical stage biopharmaceutical company, Hikma Pharmaceuticals PLC, a multigenerational generics company and G1 Therapeutics Inc., a biotechnology clinical development company. She currently serves as a Wharton Business School Leadership Advisor. The Caladrius Board has concluded that Ms. Schwalm should continue serving as a Director based upon her pharmaceutical industry, management and scientific training and experience. The Audit Committee consists of four directors: Dr. Brown (Chairman), Messrs. Klosk and Myers and Ms. Schwalm. The Science and Technology Committee consists of Drs. Traber (Chairman), Brown, Mazzo, Mr. Klosk and Ms. Schwalm. The following table sets forth information on all compensation to Caladrius' directors (other than as reflected in the Summary Compensation Table) for the year ended December 31, 2019. Cynthia S. Schwalm: Fees Earned or Paid in Cash $52,500; Stock Awards $59,999; Total Compensation $112,499.
2021-04-28	Cynthia S. Schwalm was appointed to the Caladrius Board in November 2018. ... The Audit Committee consists of four directors: Dr. Brown (Chairman), Messrs. Klosk and Myers and Ms. Schwalm. ... The Science and Technology Committee consists of Drs. Davidson (Chairman), Brown, Traber, Mazzo, Mr. Klosk, Ms. Schwalm and Ms. Whitaker. ... The following table sets forth information on all compensation to Caladrius' directors (other than as reflected in the Summary Compensation Table) for the year ended December 31, 2020. ... Cynthia S. Schwalm $52,500 Fees Earned in Cash, $59,998 Stock Awards, $0 Option Awards, $112,498 Total Compensation.

Filing Date

Source Excerpt

2020-04-29

Ms. Schwalm currently serves on the board of Kadmon Group, Inc., a clinical stage biopharmaceutical company, Hikma Pharmaceuticals PLC, a multigenerational generics company and G1 Therapeutics Inc., a biotechnology clinical development company. She currently serves as a Wharton Business School Leadership Advisor. The Caladrius Board has concluded that Ms. Schwalm should continue serving as a Director based upon her pharmaceutical industry, management and scientific training and experience. The Audit Committee consists of four directors: Dr. Brown (Chairman), Messrs. Klosk and Myers and Ms. Schwalm. The Science and Technology Committee consists of Drs. Traber (Chairman), Brown, Mazzo, Mr. Klosk and Ms. Schwalm. The following table sets forth information on all compensation to Caladrius' directors (other than as reflected in the Summary Compensation Table) for the year ended December 31, 2019. Cynthia S. Schwalm: Fees Earned or Paid in Cash $52,500; Stock Awards $59,999; Total Compensation $112,499.

2021-04-28

Cynthia S. Schwalm was appointed to the Caladrius Board in November 2018. ... The Audit Committee consists of four directors: Dr. Brown (Chairman), Messrs. Klosk and Myers and Ms. Schwalm. ... The Science and Technology Committee consists of Drs. Davidson (Chairman), Brown, Traber, Mazzo, Mr. Klosk, Ms. Schwalm and Ms. Whitaker. ... The following table sets forth information on all compensation to Caladrius' directors (other than as reflected in the Summary Compensation Table) for the year ended December 31, 2020. ... Cynthia S. Schwalm $52,500 Fees Earned in Cash, $59,998 Stock Awards, $0 Option Awards, $112,498 Total Compensation.

Data sourced from SEC filings. Last updated: 2025-08-30